{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:24:04Z","timestamp":1758273844955},"reference-count":26,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2023,4,25]]},"DOI":"10.1272\/jnms.jnms.2023_90-207","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T22:13:48Z","timestamp":1685398428000},"page":"194-201","source":"Crossref","is-referenced-by-count":1,"title":["Change in Serum KL-6 Level during Biologic Treatment for Psoriasis"],"prefix":"10.1272","volume":"90","author":[{"given":"Toshihiko","family":"Hoashi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ichiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kanda N, Hoashi T, Saeki H. Nutrition and psoriasis. Int J Mol Sci. 2020 Jul;21 (5):5405.","DOI":"10.3390\/ijms21155405"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kanda N, Hoashi T, Saeki H. The defect in regulatory T cells in psoriasis and therapeutic approaches. J Clin Med. 2021 Aug;10 (17):3880.","DOI":"10.3390\/jcm10173880"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020 Mar;47 (3):201-22.","DOI":"10.1111\/1346-8138.15196"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ozaki S, Ichiyama S, Ito M, Hoashi T, Kanda N, Saeki H. Real-world blood examination screening data before initiation of biologics for psoriasis patients. J Dermatol. 2022;49 (5):534-8.","DOI":"10.1111\/1346-8138.16333"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mabuchi T, Yamaoka H, Kawai M, Ota T, Ozawa A. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-\u03b1 inhibitor in patients with psoriasis. J Dermatol. 2014;41 (12):1136-7.","DOI":"10.1111\/1346-8138.12681"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yanaba K, Umezawa Y, Sakakihara R, et al. Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis. J Dermatol. 2015;42 (8):828-9.","DOI":"10.1111\/1346-8138.12918"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Higashi Y, Tada K, Shimokawa M, Kawai K, Kanekura T. Elevation of serum KL-6 in patients with psoriasis treated with anti-tumor necrosis factor-\u03b1 therapy. Clin Exp Dermatol. 2016;41 (1):88-90.","DOI":"10.1111\/ced.12544"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hayashi M, Yanaba K, Umezawa Y, Asahina A, Nakagawa H. Impact of anti-tumor necrosis factor-a agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis. J Dermatol. 2016;44 (9):1063-6.","DOI":"10.1111\/1346-8138.13837"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chijiwa C, Takeoka S, Kamata M, et al. Secukinumab decreases serum Kreb von den Lugen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level. Br J Dermatol. 2018;179 (6):1396-7.","DOI":"10.1111\/bjd.16993"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kurita M, Kikuchi S, Umezawa Y, Asahina A, Nakagawa H, Yanaba K. Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab. J Dermatol. 2019;46 (4):e115-6.","DOI":"10.1111\/1346-8138.14630"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hara H, Miyagawa H, Araya J, et al. Effect of anti-interleukin-17 biologics on Kreb von den Lugen-6 level in patients with psoriasis. J Dermatol. 2021;48 (6):886-93.","DOI":"10.1111\/1346-8138.15895"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iwata H, Haga N, Sugai T, Fujita Y. Serum Krebs von den Lugen-6 levels in psoriatic patients under treatment with biologics. J Dermatol. 2021;48 (3):376-9.","DOI":"10.1111\/1346-8138.15665"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Miyazaki S, Ozaki S, Ichiyama S, et al. Changes in antinuclear antibody titers over time during biologic treatment for psoriasis. J Nippon Med Sch. 2022;90:96-102.","DOI":"10.1272\/jnms.JNMS.2023_90-115"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Harigai M, Takamura A, Atsumi T, et al. Elevation of KL-6 levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDS. Mod Rheumatol. 2013;23 (2):284-96.","DOI":"10.3109\/s10165-012-0657-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takamura A, Hirata S, Nagasawa H, et al. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for safety of Biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol. 2013;23 (2):297-303.","DOI":"10.3109\/s10165-012-0658-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant. 2013 Mar;48 (3):452-8.","DOI":"10.1038\/bmt.2012.244"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-\u03b1 from cells. Nature. 1997;385 (6618):729-33.","DOI":"10.1038\/385729a0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6\/MUC1 in the clinical management of interstitial lung disease. Respir Investig. 2012;50 (1):3-13.","DOI":"10.1016\/j.resinv.2012.02.001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mi S, Li Z, Yang HZ, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-\u03b2-1 dependent and -independent mechanism. J Immunol. 2011;187 (6):3003-14.","DOI":"10.4049\/jimmunol.1004081"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Miyagawa H, Hara H, Araya J, et al. Characteristics of anti-IL-17\/23 biologics-induced interstitial pneumonia in patients with psoriasis. PLoS One. 2021;16 (1):e0245284.","DOI":"10.1371\/journal.pone.0245284"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kajihara I, Yamada-Kanazawa S, Maeda-Otsuka S, et al. Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris. J Dermatol. 2017;44 (12):e322-3.","DOI":"10.1111\/1346-8138.13986"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hayashi M, Igarashi A, Okumura K, Suzuki T. Paradoxical exacerbation of latent pneumonia by secukinumab in a patient with psoriasis vulgaris. Br J Dermatol. 2019;180 (3):684-5.","DOI":"10.1111\/bjd.17424"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lee SG, An JH, Kim DH, Yoon MS, Lee HJ. A case of interstitial lung disease and autoimmune thyroiditis associated with ustekinumab. Acta Derm Venereol. 2019;99 (3):331-2.","DOI":"10.2340\/00015555-3084"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Matsumoto Y, Abe N, Tobita R, et al. The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis. Clin Exp Dermatol. 2020;45 (7):853-8.","DOI":"10.1111\/ced.14259"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Oka R, Inoue T, Hashimoto A, Tsuruta N, Nagase K, Sugita K. Improvement of ixekizumab-related interstitial pneumonia following its discontinuation in a patient with psoriatic arthritis. Eur J Dermatol. 2020;32 (2):281-2.","DOI":"10.1684\/ejd.2022.4251"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ishibashi M, Shiiyama R. A case of psoriasis vulgaris treated with brodalmab in a hemodialysis patient with end-stage renal disease due to diabetic nephropathy. Case Rep Dermatol Med. 2020;3863152.","DOI":"10.1155\/2020\/3863152"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/2\/90_JNMS.2023_90-207\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T04:08:31Z","timestamp":1685765311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/2\/90_JNMS.2023_90-207\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2023_90-207","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"JNMS.2023_90-207"}}